{"id":"NCT00350636","sponsor":"Watson Pharmaceuticals","briefTitle":"A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo","officialTitle":"Multi-Center, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Daily Dosing With Oxybutynin Topical Gel to Treat the Symptoms of Overactive Bladder With a 14-Week Open-Label Safety Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-05","completion":"2007-05","firstPosted":"2006-07-11","resultsPosted":"2010-05-10","lastUpdate":"2010-05-10"},"enrollment":789,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Overactive Bladder"],"interventions":[{"type":"DRUG","name":"Oxybutynin topical gel","otherNames":["Oxybutynin"]},{"type":"OTHER","name":"Placebo topical gel","otherNames":["Placebo"]}],"arms":[{"label":"Oxybutynin topical gel","type":"EXPERIMENTAL"},{"label":"Placebo topical gel","type":"PLACEBO_COMPARATOR"}],"summary":"A new drug for overactive bladder is compared to placebo to determine if it is safe and effective. The study lasts approximately 12 weeks.","primaryOutcome":{"measure":"Baseline Average Number of Daily Incontinence Episodes","timeFrame":"Baseline","effectByArm":[{"arm":"Oxybutynin Topical Gel","deltaMin":5.4,"sd":3.26},{"arm":"Placebo Topical Gel","deltaMin":5.4,"sd":3.28}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":4},"locations":{"siteCount":63,"countries":["United States"]},"refs":{"pmids":["19233423","37160401"],"seeAlso":["http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":389},"commonTop":["Urinary tract infection","Headache","Upper respiratory tract infection","Dry mouth","Sinusitis"]}}